Featured Content

Duration of Benefit per Dose: RYTARY vs IR CD/LD

Hear Robert A. Hauser, MD, MBA, FAAN, discuss why he and his colleagues conducted the post hoc analysis of ADVANCE-PD.

Related Publication

Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®)

Hauser RA, et al. Jan 2021
View Publication
  • busting_myth

    Separating facts from fiction with RYTARY.

  • Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy

    Espay AJ, et al. Feb 2017
    View Publication
See more